← Eichor
Study identifier: NCT05893940 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Condition: Hematopoietic and Lymphoid System Neoplasm  ·  Sponsor: Roswell Park Cancer Institute

PhaseNA
Planned participants75
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and/or bone marrow transplant (hematopoietic cell transplantation \[HCT\]) or cellular therapy. The LIMS board delivers vibrations through the bones that may stimulate bone growth and may also increase muscle activity and strength and may also increase T-cell activation in patients planning to undergo cellular therapy. LIMS vibration therapy may stop or reverse BMD loss and/or improve the development of T-cells in the body in patients with hematologic malignancies who are undergoing or may plan to undergo HCT or cellular therapies.

This description comes directly from the study's public registry record.

Talk to the study team

Megan Herr, MD  ·  716-845-3557  ·  Megan.Herr@roswellpark.org

Always discuss trial participation with your own doctor first.

Locations (1)

Roswell Park Comprehensive Cancer CenterBuffalo, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05893940